Agreement for Global Strategic Collaboration with Kura Oncology to Develop and Commercialize Ziftomenib

November 21, 2024

This document is used only for the purpose of providing the information to investors. Though it may contain the information concerning pharmaceutical products (including products under development), it is not for the purpose of promotion, advertising, or medical advice.

Kyowa Kirin R&D Meeting

September 26, 2024

Orchard Therapeutics IR Meeting

April 8, 2024

Kyowa Kirin R&D Meeting

December 11, 2023

Agreement to acquire shares of Orchard Therapeutics

October 5, 2023

Kyowa Kirin ESG Meeting (Under construction)

October 3, 2023

Kyowa Kirin R&D Meeting

December 5, 2022

Kyowa Kirin ESG Meeting

October 12, 2022

40th Annual J.P. Morgan Healthcare Conference

January 10, 2022

The webcast will be available until January 13, 2023.

Update on KHK4083

October 4, 2021 (Material added on November 5, 2021)

Kyowa Kirin ESG Briefing

September 8, 2021

Joint Development and Commercial Agreement of KHK4083 with Amgen

June 1, 2021

R&D Day

December 10, 2020

Updates on Nourianz marketing strategy in the U.S. and KW-6356 development

November 19, 2019

Update on KHK4083: A phase 1 study in subjects with atopic dermatitis

December 3, 2018

Update on burosumab (KRN23): Clinical and regulatory updates, and pre-launch activities in the US and EU

October 27, 2017